StreetInsider.com News Articles

Form 144 Inspire Medical Systems, Filed by: Kelly Jason P

Fri, 07 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260807/26891090.html

Form 144 Inspire Medical Systems, Filed by: Kelly Jason P

Fri, 07 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260807/26891090.html

Form 4 Inspire Medical Systems, For: Jul 31 Filed by: Mann Melissa

Tue, 04 Aug 2026 20:26:00 -0400

si-local-file:///var/storage/secattach/20260804/26868571.html

Form 4 Inspire Medical Systems, For: Jul 31 Filed by: Mann Melissa

Tue, 04 Aug 2026 20:26:00 -0400

si-local-file:///var/storage/secattach/20260804/26868571.html

Inspire Medical Systems (INSP) PT Raised to $75 at Stifel

Tue, 04 Aug 2026 10:00:01 -0400

(Updated - August 4, 2026 10:00 AM EDT)

Stifel analyst Jonathan Block raised the price target on Inspire Medical Systems (NYSE: INSP) to $75.00 (from $65.00) while maintaining a Buy rating.

The analyst commented, "The first step is to stop the bleeding, which Inspire accomplished this evening. After a handful of 2026 negative guidance revisions, Inspire reported 2Q26 revenue ahead of consensus and modestly increased the bottom-end of 2026 revenue guidance, while more meaningfully increasing EPS. The environment has been tumultuous over the past ~9 months, with what was anticipated to be a big reimbursement tailwind, turning to uncertainty, and then a

Inspire Medical Systems (INSP) PT Raised to $75 at Stifel

Tue, 04 Aug 2026 10:00:01 -0400

(Updated - August 4, 2026 10:00 AM EDT)

Stifel analyst Jonathan Block raised the price target on Inspire Medical Systems (NYSE: INSP) to $75.00 (from $65.00) while maintaining a Buy rating.

Inspire Medical Systems (INSP) PT Raised to $60 at Piper Sandler

Tue, 04 Aug 2026 08:58:29 -0400

(Updated - August 4, 2026 8:58 AM EDT)

Piper Sandler analyst Adam Maeder raised the price target on Inspire Medical Systems (NYSE: INSP) to $60.00 (from $55.00) while maintaining a Neutral rating.

The analyst commented: "Q2 A Step In The Right Direction, But Still More Work To Do; INSP reported at Q2 beat with revenue of $200.6M vs. the Street's $195M forecast, while adj. EPS of $0.14 compared to the Street's -$0.25 bogey. Management increased its FY2026 guidance across-the-board after cutting guidance last quarter, including revenue of $835-875M (-8% to -4% y/y) from $825-875M (-10% to -4% y/y), adj. op margin of

Inspire Medical Systems (INSP) PT Raised to $60 at Piper Sandler

Tue, 04 Aug 2026 08:58:29 -0400

(Updated - August 4, 2026 8:58 AM EDT)

Piper Sandler analyst Adam Maeder raised the price target on Inspire Medical Systems (NYSE: INSP) to $60.00 (from $55.00) while maintaining a Neutral rating.

KeyBanc Reiterates Sector Weight Rating on Inspire Medical Systems (INSP)

Tue, 04 Aug 2026 08:53:28 -0400

KeyBanc analyst Brett Fishbin reiterated a Sector Weight rating on Inspire Medical Systems (NYSE: INSP).

The analyst commented: "Maintain SW post 2Q. We believe investors will view 2Q earnings as directionally positive, given INSP appears to have found a floor around 2026 reimbursement uncertainty. More specifically: 1) revenue was modestly ahead of subdued expectations, as the impact from previously communicated headwinds was somewhat less impactful than estimated; 2) INSP increased its 2026 outlook for revenue and earnings, primarily to account for 2Q outperformance; and 3) INSP announced a strategic restructuring to support LT revenue growth. Raising estimates for results and guidance."

For

Inspire Medical Systems (INSP) PT Raised to $60 at RBC Capital

Tue, 04 Aug 2026 08:45:41 -0400

(Updated - August 4, 2026 8:45 AM EDT)

RBC Capital analyst Shagun Singh raised the price target on Inspire Medical Systems (NYSE: INSP) to $60.00 (from $45.00) while maintaining a Sector Perform rating.

The analyst commented: "Strategic Growth Plan is a Good Step, But Visibility Remains Limited; Our View: INSP delivered a Q2 beat/raise with revenue of $201MM (down 7.6% y/y) ahead of cons/$195MM and adj. OM of 1.6% vs. a guided operating loss, sending the stock up ~15% on growth plan and disciplined P&L management. INSP narrowed full-year coding impact ($120-130MM from $120-150MM), and announced growth reinvestment via Project Horizon that

Inspire Medical Systems (INSP) PT Raised to $60 at RBC Capital

Tue, 04 Aug 2026 08:45:41 -0400

(Updated - August 4, 2026 8:45 AM EDT)

RBC Capital analyst Shagun Singh raised the price target on Inspire Medical Systems (NYSE: INSP) to $60.00 (from $45.00) while maintaining a Sector Perform rating.

Inspire Medical Systems (INSP) PT Raised to $60 at JPMorgan

Tue, 04 Aug 2026 08:12:24 -0400

JPMorgan analyst Robbie Marcus raised the price target on Inspire Medical Systems (NYSE: INSP) to $60.00 (from $54.00) while maintaining a Neutral rating.

Inspire Medical Systems (INSP) PT Raised to $62 at Truist Securities

Tue, 04 Aug 2026 07:09:53 -0400

Truist Securities analyst Richard Newitter raised the price target on Inspire Medical Systems (NYSE: INSP) to $62.00 (from $54.00) while maintaining a Hold rating.

Oppenheimer 'Tactically' Upgrades Inspire Medical Systems (INSP) to Outperform 'Despite Noisy Fundamentals'

Tue, 04 Aug 2026 06:52:00 -0400

(Updated - August 4, 2026 6:52 AM EDT)

Oppenheimer analyst Suraj Kalia upgraded Inspire Medical Systems (NYSE: INSP) from Perform to Outperform with a price target of $85.00.

The analyst comments "INSP's 2Q revenues of $201M slightly outpaced our/consensus $195M/$195M estimates, driven by a surprise OUS contribution (distributor stocking unclear). Our anti-consensus thesis of limited HGNS TAM and mixed outcomes has played out, and we expect US reimbursement drama to continue. However, at these levels, there is "noisy" value to the story as an MSD-HSD grower; hence, we are upgrading the stock to OP/$85 PT. Our residual concerns: 1) Medicare billing for

Oppenheimer 'Tactically' Upgrades Inspire Medical Systems (INSP) to Outperform 'Despite Noisy Fundamentals'

Tue, 04 Aug 2026 06:52:00 -0400

(Updated - August 4, 2026 6:52 AM EDT)

Oppenheimer analyst Suraj Kalia upgraded Inspire Medical Systems (NYSE: INSP) from Perform to Outperform with a price target of $85.00.

Oppenheimer 'Tactically' Upgrades Inspire Medical Systems (INSP) to Outperform 'Despite Noisy Fundamentals'

Tue, 04 Aug 2026 06:52:00 -0400

(Updated - August 4, 2026 6:52 AM EDT)

Oppenheimer analyst Suraj Kalia upgraded Inspire Medical Systems (NYSE: INSP) from Perform to Outperform with a price target of $85.00.

Oppenheimer 'Tactically' Upgrades Inspire Medical Systems (INSP) to Outperform 'Despite Noisy Fundamentals'

Tue, 04 Aug 2026 06:52:00 -0400

(Updated - August 4, 2026 6:52 AM EDT)

Oppenheimer analyst Suraj Kalia upgraded Inspire Medical Systems (NYSE: INSP) from Perform to Outperform with a price target of $85.00.

Inspire Medical Systems (INSP) PT Raised to $65 at Mizuho

Tue, 04 Aug 2026 06:39:57 -0400

Mizuho analyst Anthony Petrone raised the price target on Inspire Medical Systems (NYSE: INSP) to $65.00 (from $55.00) while maintaining a Outperform rating.

Inspire Medical Systems (INSP) PT Raised to $59 at Baird

Tue, 04 Aug 2026 06:13:31 -0400

Baird analyst David Rescott raised the price target on Inspire Medical Systems (NYSE: INSP) to $59.00 (from $54.00) while maintaining a Neutral rating.

Form 10-Q Inspire Medical Systems, For: Jun 30

Mon, 03 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260803/26857838.html

Form 10-Q Inspire Medical Systems, For: Jun 30

Mon, 03 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260803/26857838.html

Mobia Medical names Myriam Curet to its board of directors

Mon, 03 Aug 2026 16:05:34 -0400

Mobia Medical, Inc. (Nasdaq: MOBI) announced the appointment of Myriam Curet, M.D., as an independent director to its board, effective July 30, 2026, according to a company statement.

Dr. Curet has served as a Clinical Professor of Surgery at Stanford University School of Medicine since 2015, following a series of faculty positions in Stanford's Department of Surgery from 2000 to 2015. She has also held a part-time clinical appointment at the Palo Alto Veterans Administration Medical Center since October 2010.

Earlier in her career, Dr. Curet was an Associate Professor of Surgery at the University of New Mexico from 1994 to 2000

Mobia Medical names Myriam Curet to its board of directors

Mon, 03 Aug 2026 16:05:34 -0400

Mobia Medical, Inc. (Nasdaq: MOBI) announced the appointment of Myriam Curet, M.D., as an independent director to its board, effective July 30, 2026, according to a company statement.

Earlier in her career, Dr. Curet was an Associate Professor of Surgery at the University of New Mexico from 1994 to 2000

Inspire Medical Systems (INSP) Tops Q2 EPS by 38c, Beats on Revenue; Offers FY26 Revenue Guidance

Mon, 03 Aug 2026 16:05:04 -0400

Inspire Medical Systems (NYSE: INSP) reported Q2 EPS of $0.14, $0.38 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $200.6 million versus the consensus estimate of $194.67 million.

GUIDANCE:

Inspire Medical Systems sees FY2026 revenue of $835-875 million, versus the consensus of $843 million.

For earnings history and earnings-related data on Inspire Medical Systems (INSP) click here.

Inspire Medical Systems (INSP) Tops Q2 EPS by 38c, Beats on Revenue; Offers FY26 Revenue Guidance

Mon, 03 Aug 2026 16:05:04 -0400

GUIDANCE:

Inspire Medical Systems sees FY2026 revenue of $835-875 million, versus the consensus of $843 million.

For earnings history and earnings-related data on Inspire Medical Systems (INSP) click here.